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ABSTRACT 
Tramadol is used in treatment of moderate to severe pain. Nowadays tramadol overdose is one of the 
common emergencies. Naloxone is an antagonist which is used as a first step of treatment in these 
patients. This study was designed to evaluate the seizurogenic effects of naloxone in tramadol overdose. 
A number of 124 patients with the diagnosis of tramadol overdose were divided to receive low-doses of 
intravenous naloxone (0.8 mg, case group) or just supportive cares (control group). All patients in case 
and control groups were observed by a single emergency resident and fallowed for 1.5 hours to 
document the happening of seizures. In the naloxone group, incidence of seizure was higher than in 
control group. The possibility of seizure occurrence was significantly higher in naloxone group than the 
control group (p<0.05). In conclusion, naloxone induced a seizurogenic effect in patients with tramadol 
overdose. This finding could be considered in the management of patients with tramadol overdose. 
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Tramadol is a centrally-acting analgesic commonly 
used in the treatment of moderate to severe pain. 
Tramadol produces its anti-noceptive and analgesic 
effects via opioid and non-opioid mechanisms. The 
opioid component involves low affinity to μ-opioid 
receptors and the non-opioid component inhibits the 
reuptake of serotonin and norepinephrine 
neurotransmitters [
As one possible method for reducing drug-related 
deaths caused by opioid overdose, two significant 
adverse reactions which known to potentially occur with 
tramadol - seizures and serotonin syndrome- could 
dramatically be controlled by naloxone. Therefore, most 
guidelines for treatment of opioid overdose recommend 
short-acting opioid antagonist naloxone as the first step 
of treatment after supportive care [ 4]. Naloxone, is a 
phenanthrene compound structurally related to 
morphine. It was the first opiate receptor antagonist 
introduced in clinical practice [ 5] and has been widely 
used to antagonize the effects of opiate drugs. Indeed, 
most of biological effects of the analgesics have been 
long classified as opiate or non-opiate depending on 
whether or not they were reversed by naloxone [ 6]. 
 1]. Initially this new opioid painkiller 
medication was introduced as having safe and low abuse 
liability and widely used throughout the word. 
However, after a while, it was revealed that this agent 
has significant risks when overdose occurs. Nowadays, 
tramadol abuse has become a common medical 
emergency. The US Food and Drug Administration 
(FDA) MEDWATCH system has received hundreds of 
reports of tramadol-associated abuse, dependence, and 
withdrawal [
Despite all advantages of naloxone, recent data 
showed serious adverse effects including several 
instances of seizures following naloxone administration 
[
 2]. Among opioids listed in the 2001 and 
2002 annual reports of the American Association of 
Poison Control Centres Toxic Exposure Surveillance 
System, tramadol was ranked second to oxycodone in 
number of exposure cases [
 7]. Although the seizurogenic effects of low-dose 
naloxone in tramadol overdose has been reported rarely, 
but it could increase the mortality in patient whose in 
risk of seizure. This study was designed to evaluate the  3]. 
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Table 1. Demographic characteristics of 124 patients with tramadol overdose 
Variable Case* (N = 62) 
Control** 
(N = 62) p value 
Age(year) 26.33 29.46 0.5 
Male 59 55 0.18 
Female 3 7 — 
Single 35 27 0.15 
Married  27 35 — 
p value less than 0.05 considered significant 
*The Cases received low-doses of naloxone, **The Controls received just supportive care. 
role of naloxone in inducing seizure among patients 
with tramadol overdose. 
METHODS AND MATERIALS  
This study was conducted over a 12-month period 
from July 2008 to July 2009 in our University Hospital. 
One hundred twenty-four patients (age range: 17-58 
years) of both genders with the diagnosis of tramadol 
overdose were allocated by randomization list to receive 
supportive care and low-doses of naloxone (case group) 
or just supportive care (control group). Participants were 
equally divided in two groups (case and control). 
Exclusion criteria consisted of being pregnant, those 
overdoses with multi-drug abuse and risk factors of 
seizure including electrolytes imbalance, low blood 
sugar or abnormal blood urea nitrogen (BUN) and 
creatinine. The patients in case group, in addition to 
usual supportive cares received 0.8 mg single dose 
intravenous (IV) naloxone. The patients in control group 
just received supportive care. The tramadol 
concentration were estimated with urine analysis on 
admission in the emergency ward using gas 
chromatography-mass spectrometry and it was 
considered positive if it showed high peak of tramadol 
of magnitude greater than the therapeutic range (0.1 to 
0.3 mg/L). 
All patients in case and control groups were 
observed by a single emergency resident and fallowed 
for 1.5 hours to document the happening of seizure. 
This short period was selected due to the short half-life 
of naloxone. The diagnosis of seizure was based on the 
onset of jerky movements of whole body, tonic and 
colonic spasms and convulsions which recorded as 
qualitative measures of experimental seizure activity.  
All patients prognosis were observed in Emergency 
Department, and in case of occurring a life-threatening 
problem such as respiratory apnea or significant 
decrease in the level of consciousness, the patient were 
dropped out from the study and received advanced life 
support, naloxone, etc. They were discharged from the 
hospital after 24 hours if they were alert and 
cooperative. The study was undertaken after obtaining 
institutional ethics committee approval and subjects 
were enrolled only after obtaining informed coasted 
from the subjects. 
Statistical analyses were performed with SPSS 16.0 
Software for Windows. Demographic data, doses of 
drug and time of hospital referral after drug abuse were 
compared between case and control groups using the 
student t-test. Nominal data like gender, marital status 
or history of seizure were compared between groups 
using the chi-square or Fisher's exact test. Logistic 
regression was used to determine the effects of different 
past medical history of drugs and diseases on the 
outcomes. Data were presented as mean, median value 
of 25%-75% SD. All p values are two tailed. The 
p<0.05 was taken as statistically significant. 
RESULTS 
The study involved 124 patients, with 62 patients in 
each group with a mean (SD) age of 27 (3) years. Table 
1 demonstrates demographic characteristics of the 
studied population. There were no significant 
differences between the two groups with regard to 
demographic data like age, gender and marital status. 
No patient was dropped out from the study. The doses 
Table 2. Comparison of past medical history of the patients with tramadol overdose between the two studied groups (N = 124) 
 Case† (N = 62) 
Control†† 
(N = 62) p value 
Former drug overdose 24 34 0.07 
Former tramadol overdose 8 7 0.78 
History of seizure 3 5 0.71 
CNS1 disease 3 5 0.38 
Alcoholism 0 1 1.00 
Cigarette smoking 52 45 0.12 
1Central Nervous System 
†The Cases received low-doses of naloxone, ††The Controls received just supportive care. 
p value less than 0.05 considered significant. 
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Table 3. Clinical outcomes of the patients with tramadol overdose between the two studied groups (N = 124) 
 
Case† 
(n = 62) 
N (%) 
Control†† 
(n = 62) 
N (%) 
p value 
Seizure  15 (24%) 6 (9%) 0.02** 
Serotonin Syndrome 0 (0%) 0 (0%) 0.83 
Apnea 6 (9.6%) 4 (6.4%) 0.52 
Loss of consciousness 12 (19.3%) 4 (6.4%) 0.2 
†The Cases received low-doses of naloxone, ††The Controls received just supportive care. 
**p value less than 0.05 considered significant. 
of tramadol abuse and the time of presentation to the 
hospital were significantly different between the two 
studied groups (p<0.05). 
The history of alcoholism and smoking, central 
nervous system (CNS) disorders, history of previous 
tramadol or non-tramadol drug abuses and tramadol 
overdoses or tramadol- induced seizures were not 
significantly different between case and control groups 
(p>0.05) (Table 2). We evaluated the possible effect of 
all past medical events which may induce seizures. The 
only variable which significantly contributed in 
inducing seizures was previous tramadol overdose 
(p<0.05). 
In both groups, symptoms reported with overdose 
were: lethargy 26 (30%), nausea 12 (14%), tachycardia 
11 (13%), agitation 9 (10%), seizures 7 (8%), 4 each 
(5%) of coma and hypertension, and respiratory 
depression 2 (2%). 
Clinical outcomes between case and control groups 
were followed during the hospitalization period (7 days 
in mean). In the naloxone group, incidence of seizure 
was significantly higher than in control group (15 
patients in naloxone group vs. 6 patients in control 
group; p<0.05).  But, there was no significant difference 
in other clinical outcomes such as loss of consciousness, 
serotonin syndrome or respiratory apnea between cases 
and controls (Table 3). 
DISCUSSION 
In the present study, we found that low doses of 
naloxone could increase the risk of seizure in patients 
with tramadol overdose. However, the history of 
previous tramadol overdose could have a coefficient 
effect on the side effect of naloxone. Although tramadol 
is a novel analgesic possessing which is used in the 
management of moderate to severe pain, there are some 
studies on the adverse effects of toxicity in overdoses 
due to different mechanisms like opioid-dependent 
gamma-aminobutyric acid inhibitory pathway [ 8] or 
histamine (H1 receptor) involvement [ 9] which could 
cause tramadol-induced seizures [ 10].  Furthermore, 
opioid antagonist naloxone which is recommended for 
taramdol overdose has controversial effects. Some 
studies indicated that administration of naloxone 
markedly attenuate this tramadol-induced potentiating 
of seizurogenic activity [ 11]. But on the other hand, 
other studies indicate that naloxone markedly increased 
colonic seizure [ 12] and even some of them showed that 
naloxone did not modify the reaction of tramadol 
seizurogenic effects [ 13]. Different susceptibility in 
some especial groups and studies could happen by the 
different personality characteristics like age and race. In 
addition, with regard to abuse and/or overdose, 
neurotoxicity of tramadol is speculated to be related to 
the reuptake inhibition of serotonin and norepinephrine 
rather than its opioid effects. Patients will be at risk of 
seizure as an adverse effect itself [ 14] and naloxone 
seizurogenic effect could put them in a worse condition. 
It may be concluded that naloxone induced a 
seizurogenic effect in patients with tramadol overdose 
in Iranian young patients. With respect to high risk of 
seizure further experimentation may be useful to 
determine the mechanism of naloxone effect on 
tramadol overdose and other related biochemical 
changes occurring in the CNS and thus resulting in 
seizurogenic effects of naloxone especially in tramadol 
overdoses patients. Consequently, the therapeutic effect 
of naloxone in tramadol overdoses patients is still 
controversial. Our study sample was too small to certify 
the point. We also were not able completely to match 
the case and control groups in dosage abused and time 
of referral to hospital after intoxication and couldn’t set 
the study as a randomized trial which were limitations 
of this study. But as a conclusion, we recommend until 
the certain general opinion on this issue, clinicians 
prescribe the naloxone with caution and only in special 
clinical indications like respiratory apnea.  
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